Loading clinical trials...
Loading clinical trials...
A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple-Ascending Dose Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY4088044 in Healthy Participants.
Conditions
Interventions
LY4088044
LY4088044
+2 more
Locations
6
United States
Collaborative Neuroscience Network - CNS
Los Alamitos, California, United States
ICON
Lenexa, Kansas, United States
ICON Early Phase Services
San Antonio, Texas, United States
ICON
Salt Lake City, Utah, United States
New Zealand Clinical Research Christchurch
Christchurch, New Zealand
Lilly Centre for Clinical Pharmacology
Singapore, Singapore
Start Date
July 24, 2025
Primary Completion Date
July 1, 2027
Completion Date
July 1, 2027
Last Updated
April 20, 2026
NCT00104325
NCT03878121
NCT06655324
NCT07526506
NCT06431932
NCT06716502
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
CONTACT
1-317-615-4559LillyTrials@Lilly.comPhysicians interested in becoming principal investigators please contact
CONTACT
clinical_inquiry_hub@lilly.comLead Sponsor
Eli Lilly and Company
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions